Form 4: BeOne Medicines GC Executes 10b5-1 Plan, Sells Shares

BeOne Medicines' SVP and General Counsel, Lee Chan Henry, executed a Rule 10b5-1 trading plan, exercising stock options and selling American Depositary Shares.

Summary

• SVP, General Counsel Lee Chan Henry of BeOne Medicines Ltd. executed transactions on November 12, 2025, under a Rule 10b5-1 trading plan adopted on May 14, 2025.
• Exercised share options to acquire a total of 996 American Depositary Shares (ADS), which represent 13 Ordinary Shares each.
• The options exercised had strike prices of $14.96 (3,926 options), $16.41 (5,174 options), and $12.23 (3,848 options) per Ordinary Share.
• Simultaneously sold 996 American Depositary Shares (ADS) at weighted average prices of $348.75 and $350.00 per ADS.
• Following these transactions, the reporting person directly owns 0 American Depositary Shares.
• Remaining beneficially owned derivative securities include 35,698, 103,935, and 123,214 share options with various vesting schedules and expiration dates.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction under a 10b5-1 plan, which is generally neutral. The executive realized significant gains from option exercises and sales, which is positive for the individual but the sale itself can be viewed with slight caution by the market, though mitigated by the pre-planned nature.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and non-discretionary sale, which can mitigate concerns about insider trading.
• The sale prices of the American Depositary Shares ($348.75 and $350.00) are significantly higher than the exercise prices of the underlying options (ranging from $12.23 to $16.41 per Ordinary Share, which translates to much lower per-ADS cost), indicating a profitable transaction for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, suggesting a lack of confidence, although this is often for personal financial planning.
• The reporting person's direct beneficial ownership of American Depositary Shares is now 0 following these transactions.

Future Outlook

NA

Industry Context

This is a routine insider transaction under a 10b5-1 plan, common across industries for executive compensation and personal financial management. It does not inherently reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a standard practice for corporate insiders to sell company stock while adhering to insider trading regulations, demonstrating compliance with industry best practices for executive stock transactions.
• The significant difference between option exercise prices (e.g., $12.23 per Ordinary Share) and ADS sale prices (e.g., $350.00 per ADS, which implies $26.92 per Ordinary Share based on 13 Ordinary Shares per ADS) indicates substantial gains for the executive, which is typical for long-term incentive plans in successful companies.

Stakeholder Impact

• Shareholders: The sale by a senior executive, even if pre-planned, could be interpreted by some as a signal, though the 10b5-1 plan mitigates this. The profitable nature of the transaction for the executive might be viewed positively as a reward for performance.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a pre-planned insider transaction by the SVP, General Counsel, involving the exercise of stock options and the subsequent sale of American Depositary Shares. While insider sales can sometimes raise concerns, the execution under a Rule 10b5-1 plan indicates a non-discretionary, pre-scheduled event for personal financial management rather than a reaction to new, undisclosed negative information. The executive realized substantial gains, which is a positive outcome for their compensation. However, the transaction itself does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing is a routine disclosure and does not present a compelling reason to alter an existing investment thesis.

Keywords

BeOne Medicines, ONC, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1, American Depositary Shares, Executive Compensation, Lee Chan Henry, SVP General Counsel